Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy

Kaidarova,Dilyara  Radikovna; Kopp,Mikhail  Valeryevich; Pokrovsky,Vadim  S.; Dzhugashvili,Мaia; Akimzhanova,Zhanna  Mukhataevna; Abdrakhmanov,Ramil  Zufarovich; Babich,Elena  Nikolaevna; Bilan,Evgeniy  Viktorovich; Byakhov,Anton  Valeryevich; Gurov,Sergey  Nikolaevich; Koroleva,Irina  Albertovna; Mochalova,Anastasiia  Sergeevna; Povaga,Svetlana  Sergeevna; Raigorodsky,Maxim  Vladimirovich; Saifullin,Arthur  Sidorovich; Sanz,Eduardo; Petrovskiy,Fedor  Igorevich

doi:10.3892/ol.2019.10868

Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy

Authors:
- Dilyara Radikovna Kaidarova
- Mikhail Valeryevich Kopp
- Vadim S. Pokrovsky
- Мaia Dzhugashvili
- Zhanna Mukhataevna Akimzhanova
- Ramil Zufarovich Abdrakhmanov
- Elena Nikolaevna Babich
- Evgeniy Viktorovich Bilan
- Anton Valeryevich Byakhov
- Sergey Nikolaevich Gurov
- Irina Albertovna Koroleva
- Anastasiia Sergeevna Mochalova
- Svetlana Sergeevna Povaga
- Maxim Vladimirovich Raigorodsky
- Arthur Sidorovich Saifullin
- Eduardo Sanz
- Fedor Igorevich Petrovskiy
View Affiliations

Affiliations: Kazakh Research Institute of Oncology and Radiology, Almaty 050000, Republic of Kazakhstan, Department of Clinical Medicine, Medical University ‘Reaviz’, Samara 443001, Russia, Department of Biochemistry, N.N. Blokhin Cancer Research Center, RUDN University, Moscow 115478, Russia, Department of Oncology Radiology, Murcia University, Murcia 30200, Spain, Department of Chemotherapy, Almaty Oncology Center, Almaty 050060, Republic of Kazakhstan, Department of Oncology, Khanty‑Mansiysk Regional Clinical Hospital, Khanty‑Mansiysk 628012, Russia, Department of Chemotherapy, Moscow Clinical Scientific Center n. a. A.S. Loginov, Moscow 111123, Russia, Department of Chemotherapy, Moscow Oncologic Clinical Dispensary No. 1, Moscow 105005, Russia, Department of Chemotherapy, Clinical Hospital No. 1 MEDSI, Moscow 143442, Russia, Department of Chemotherapy, Russian Railways Hospital at The Station Smolensk, Smolensk 214025, Russia, Department of Oncology, Medical Center ‘EVIMED’ LLC, Chelyabinsk 454048, Russia, Department of Chemotherapy, Surgut Regional Hospital, Surgut 628400, Russia, Scientific Department, Catalysis S.L., Madrid 28016, Spain, Department of Pharmacology and Clinical Pharmacology, Khanty‑Mansiysk State Medical Academy, Khanty‑Mansiysk 628011, Russia
Published online on: September 13, 2019 https://doi.org/10.3892/ol.2019.10868
Pages: 5644-5652
Copyright: © Kaidarova et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment of cancer often requires the use of adjuvant chemotherapy (ACT). In real clinical practice, numerous patients suffer from severe toxicity and reduced quality of life (QoL). Hence, there is a need to maintain QoL and to reduce therapy toxicity to comply with recommended chemotherapy (CT) regimens. The present study focused on the effects of the multi‑component nutritional supplement Oncoxin (ONCX) on QoL and CT‑induced toxicity in patients undergoing ACT. A total of 133 patients aged 50‑70 years with gastric cancer IIB‑IIIC or non‑small cell lung cancer IIB‑IIIA were enrolled in the present study: 84 received ONCX, and 49 were included in the control arm and received CT only. It was identified that after 2 weeks of treatment the patients receiving ONCX exhibited clinically meaningful improvement of QoL (measured by Edmonton Symptom Assessment System Questionnaire) compared with those in the control group (odds ratio, 2.07; 95% CI, 1.00‑4.29). By the end of a 3 week‑period, the albumin level was higher in patients of the ONCX group compared with those in the control group (mean, 38.1; 95% CI, 37.1‑39.1 g/l; vs. mean, 35.5; 95% CI, 33.9‑37.0; P=0.03; respectively). Furthermore, the use of ONCX substantively reduced the hepatic toxicity of ACT. The present prospective real clinical setting study revealed positive effects of ONCX on QoL and ACT toxicity. The present study was retrospectively registered under the study registration number NCT03550482 at ClinicalTrials.gov (June 8, 2018).

View Figures

View References

1	Prasanna T, Beith J, Kao S, Boyer M and McNeil CM: Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia Pac J Clin Oncol. 14:125–133. 2018. View Article : Google Scholar : PubMed/NCBI
2	Lakhanpal SH: Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: Primary prophylaxis with g-CSF is required. Breast Cancer Manage. 2:367–374. 2013. View Article : Google Scholar
3	Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 24:5381–5387. 2006. View Article : Google Scholar : PubMed/NCBI
4	Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K and Schmoll HJ: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 29:1465–1471. 2011. View Article : Google Scholar : PubMed/NCBI
5	André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
6	Eichler M, Singer S, Janni W, Harbeck N, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Scholz C, et al: Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: Results from the prospective randomized ADEBAR trial. Breast Cancer. 24:319–325. 2017. View Article : Google Scholar : PubMed/NCBI
7	Yan Y, Mo Y and Zhang D: Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors. Zhonghua Gan Zang Bing Za Zhi. 23:204–208. 2015.(In Chinese). PubMed/NCBI
8	Zhao H, Zhu W, Xie P, Li H, Zhang X, Sun X, Yu J and Xing L: A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer. Radiother Oncol. 110:132–136. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhao H, Xie P, Li X, Zhu W, Sun X, Sun X, Chen X, Xing L and Yu J: A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. Radiother Oncol. 114:351–356. 2015. View Article : Google Scholar : PubMed/NCBI
10	Al-Mahtab M, Akbar SM, Khan MS and Rahman S: Increased survival of patients with end-stage hepatocellular carcinoma due to intake of ONCOXIN(^®), a dietary supplement. Indian J Cancer. 52:443–446. 2015. View Article : Google Scholar : PubMed/NCBI
11	Shumsky A, Bilan E, Sanz E and Petrovskiy F: Oncoxin nutritional supplement in the management of chemotherapy- and/or radiotherapy-associated oral mucositis. Mol Clin Oncol. 10:463–468. 2019.PubMed/NCBI
12	Hui D, Shamieh O, Paiva CE, Khamash O, Perez-Cruz PE, Kwon JH, Muckaden MA, Park M, Arthur J and Bruera E: Minimal clinically important difference in the physical, emotional, and total symptom distress scores of the edmonton symptom assessment system. J Pain Symptom Manage. 51:262–269. 2016. View Article : Google Scholar : PubMed/NCBI
13	Yagi T, Asakawa A, Ueda H, Ikeda S, Miyawaki S and Inui A: The role of zinc in the treatment of taste disorders. Recent Pat Food Nutr Agric. 5:44–51. 2013. View Article : Google Scholar : PubMed/NCBI
14	Prasad AS: Impact of the discovery of human zinc deficiency on health. J Trace Elem Med Biol. 28:357–363. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sweeney JD, Ziegler P, Pruet C and Spaulding MB: Hyperzincuria and hypozincemia in patients treated with cisplatin. Cancer. 63:2093–2095. 1989. View Article : Google Scholar : PubMed/NCBI
16	Ciubotariu D, Ghiciuc CM and Lupușoru CE: Zinc involvement in opioid addiction and analgesia-should zinc supplementation be recommended for opioid treated persons? Subst Abuse Treat Prev Policy. 4:10–29. 2015.
17	Weinstein SJ, Stolzenberg-Solomon R, Pietinen P, Taylor PR, Virtamo J and Albanes D: Dietary factors of one-carbon metabolism and prostate cancer risk. Am J Clin Nutr. 84:929–935. 2006. View Article : Google Scholar : PubMed/NCBI
18	Buijs N, Luttikhold J, Houdijk AP and van Leeuwen PA: The role of a disturbed arginine/NO metabolism in the onset of cancer cachexia: A working hypothesis. Curr Med Chem. 19:5278–5286. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ham DJ, Murphy KT, Chee A, Lynch GS and Koopman R: Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr. 33:448–458. 2014. View Article : Google Scholar : PubMed/NCBI
20	Grotz MR, Pape HC, van Griensven M, Stalp M, Rohde F, Bock D and Krettek C: Glycine reduces the inflammatory response and organ damage in a two-hit sepsis model in rats. Shock. 16:116–121. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kantor ED, Lampe JW, Navarro SL, Song X, Milne GL and White E: Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 20:479–485. 2014. View Article : Google Scholar : PubMed/NCBI
22	Dominiak K, McKinney J, Heilbrun LK and Sarkar FH: Critical need for clinical trials: An example of a pilot human intervention trial of a mixture of natural agents protecting lymphocytes against TNF-alpha induced activation of NF-kappa B. Pharm Res. 27:1061–1065. 2010. View Article : Google Scholar : PubMed/NCBI
23	Khan R, Khan AQ, Lateef A, Rehman MU, Tahir M, Ali F, Hamiza OO and Sultana S: Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats. PLoS One. 8:e560202013. View Article : Google Scholar : PubMed/NCBI
24	Prasad AS: Zinc: Mechanisms of host defense. J Nutr. 137:1345–1349. 2007. View Article : Google Scholar : PubMed/NCBI
25	Fukagawa NK and Galbraith RA: Advancing age and other factors influencing the balance between amino acid requirements and toxicity. J Nutr 134 (6 Suppl). 1569S–1574S. 2004.
26	Miller GW, Lock EA and Schnellmann RG: Strychnine and glycine protect renal proximal tubules from various nephrotoxicants and act in the late phase of necrotic cell injury. Toxicol Appl Pharmacol. 125:192–197. 1994. View Article : Google Scholar : PubMed/NCBI
27	Zhong Z, Li X, Yamashina S, von Frankenberg M, Enomoto N, Ikejima K, Kolinsky M, Raleigh JA and Thurman RG: Cyclosporin a causes a hypermetabolic state and hypoxia in the liver: Prevention by dietary glycine. J Pharmacol Exp Ther. 299:858–865. 2001.PubMed/NCBI
28	Mauriz JL, Matilla B, Culebras JM, Gonzalez P and Gonzalez-Gallego J: Dietary glycine inhibits activation of nuclear factor kappa B and prevents liver injury in hemorrhagic shock in the rat. Free Radic Biol Med. 31:1236–1244. 2001. View Article : Google Scholar : PubMed/NCBI
29	Robbins D and Zhao Y: Manganese superoxide dismutase in cancer prevention. Antioxid Redox Signal. 20:1628–1645. 2014. View Article : Google Scholar : PubMed/NCBI